HC Wainwright & Co. Maintains Buy on TScan Therapeutics, Lowers Price Target to $7
Benzinga Newsdesk 11 months ago
NewsPrice TargetAnalyst Ratings
HC Wainwright & Co. analyst Andres Y. Maldonado maintains TScan Therapeutics (NASDAQ:TCRX) with a Buy and lowers the price target from $10 to $7.
HC Wainwright & Co. analyst Andres Y. Maldonado maintains TScan Therapeutics (NASDAQ:TCRX) with a Buy and lowers the price target from $10 to $7.